Cellular Immunology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani I.R.C.C.S, Rome, Italy.
Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):415-24. doi: 10.1177/039463201202500211.
Multicolor flow cytometry allows to study the markers differentially expressed during maturation, activation, function and senescence on immune cells. Despite the availability of reagents and technology, scarce agreement has been gained regarding phenotypic markers of HIV disease progression other than CD4 T-cell count. In this work, we present a novel high-throughput global analysis of CD4 and CD8 T-lymphocyte profiles by standardized 8-color combinations of antibodies aimed at analyzing HIV disease course progression. For this purpose, two tubes with lyophilized reagent cocktails (CD4- and CD8-specific tubes) were designed to compare the immunological characteristics of HIV-infected persons (37 "high CD4" HAART-treated and 32 "low CD4" naïve or failed-treatment patients) with healthy donors (HD). In particular, T-cell activation (CD25, CD38, CD69), differentiation (CD45RA, CCR7), apoptosis (CD95) and immune suppression profiles (CD25(high)CD127-) in HIV+ patients were compared with HD. Statistical analysis was performed by identifying the parameters associated with disease progression, namely markers that were found to be significantly different between groups with high CD4 counts (including HD) and low CD4 counts (restricted to HIV patients) but not between the HD and the "high CD4" group. This set of markers, including those identifying different maturation and senescence subtypes of CD4 and CD8 T cells, was found to be associated with therapy failure, and it is in fact evaluated in an ongoing study aimed to verify its prognostic value. This robust assay was found feasible on a semi-routine scale for HIV-infected persons, and allows for broader clinical studies aimed at defining markers associated with treatment outcome, possibly having a high impact on the clinical management of HIV disease.
多色流式细胞术可用于研究免疫细胞在成熟、激活、功能和衰老过程中差异表达的标志物。尽管有试剂和技术可用,但除 CD4 T 细胞计数外,对于 HIV 疾病进展的表型标志物,尚未达成广泛共识。在这项工作中,我们提出了一种新的高通量分析 CD4 和 CD8 T 淋巴细胞谱的方法,通过标准化的 8 色抗体组合,旨在分析 HIV 疾病进展过程。为此,设计了两个装有冻干试剂鸡尾酒的管(CD4-和 CD8-特异性管),以比较 HIV 感染者(37 名接受高 CD4 值的 HAART 治疗和 32 名低 CD4 值的初治或治疗失败患者)与健康供体(HD)的免疫特征。特别是,与 HD 相比,比较了 HIV+患者的 T 细胞活化(CD25、CD38、CD69)、分化(CD45RA、CCR7)、凋亡(CD95)和免疫抑制谱(CD25(high)CD127-)。通过确定与疾病进展相关的参数进行统计分析,即发现高 CD4 计数组(包括 HD)和低 CD4 计数组(仅限于 HIV 患者)之间存在显著差异的标志物,但 HD 和“高 CD4”组之间没有差异。这组标志物包括鉴定 CD4 和 CD8 T 细胞不同成熟和衰老亚型的标志物,与治疗失败相关,实际上正在进行一项旨在验证其预后价值的研究中进行评估。该稳健的检测方法在 HIV 感染者中可在半常规范围内实施,并允许进行更广泛的临床研究,以确定与治疗结果相关的标志物,可能对 HIV 疾病的临床管理产生重大影响。